GeneDx Holdings Appoints Heidi Chen as Chief Legal Officer to Enhance Governance and Innovation

GeneDx Strengthens Leadership with Appointment of Heidi Chen as Chief Legal Officer

GeneDx Holdings, a prominent player in genomic insights focused on improving health outcomes, announces the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. Reporting directly to CEO Katherine Stueland, Chen will manage all legal, compliance, and policy functions within the company. Her extensive background in corporate governance and regulatory matters positions her as a vital asset as GeneDx navigates the complexities of the healthcare landscape, which is undergoing significant transformations. Stueland expresses confidence in Chen’s abilities to guide the company’s legal strategies and foster innovation in patient care.

Heidi Chen brings over 30 years of legal expertise to GeneDx, having previously served as General Counsel at Zoetis for nearly 12 years. During her tenure at Zoetis, she played a crucial role in establishing the legal department after the company's spinoff from Pfizer in 2013, overseeing key areas such as mergers and acquisitions, litigation, and operational strategy for human health diagnostics. Chen’s experience in these domains equips her to address the unique challenges faced by GeneDx as it seeks to enhance personalized health insights through genomic data. Her legal career began at Hughes & Hubbard and Clifford Chance, and she holds a J.D. from Cornell Law School and a B.S. from Yale University.

In her new role, Chen expresses a strong commitment to accelerating GeneDx’s growth and transforming patient care through collaboration and innovation. The company is recognized for leveraging the world’s largest rare disease data sets to advance precision medicine, which plays a crucial role in guiding diagnosis, treatment, and drug discovery. As GeneDx continues to enhance its position in the genomic health sector, Chen’s leadership is anticipated to drive strategic initiatives that uphold the company's mission of improving health outcomes through personalized insights.

In addition to her legal responsibilities, Chen’s appointment signifies GeneDx's intention to strengthen its governance framework and compliance protocols, essential in an industry marked by rapid advancements and regulatory shifts. With her extensive background, Chen is expected to foster a culture of accountability and ethical practice within GeneDx, reinforcing the company’s commitment to innovation in healthcare solutions.

For further information on GeneDx’s services and initiatives, visit www.genedx.com and connect with them on LinkedIn.